What Zacafemyl Treats: Main Uses and Benefits

Zacafemyl is generally used to manage early intrauterine pregnancy (up to 70 days gestation) as part of a medical termination regimen, and for certain cases of endogenous Cushing's syndrome marked by hyperglycemia (high blood sugar).

The primary indications for this medication address symptom clusters that may become intense or disruptive, such as the metabolic distress arising from hypercortisolism in situations where primary interventions are insufficient. This medication is applied when patients require specific support to manage certain distressing symptoms. Zacafemyl also assists in managing symptoms associated with early pregnancy loss and the size of uterine leiomyomas (fibroids).

This specialized utility provides support that helps ease the overall symptom burden, assisting patients during difficult episodes by easing distress.

Quick Fact: Support for Hypercortisolism-Related High Blood Sugar
This medication supports the management of severe hyperglycemia caused by excess cortisol, offering relevant assistance for patients with Cushing’s syndrome.

Eligibility Map: Official Regulatory Information

Regulatory authorities define Zacafemyl's eligibility through specific prohibitions, restrictions, and age-related limitations, ensuring use is confined to populations where its risks are formally understood.

Eligibility Status	Patient Population or Condition
Allowed	Adults meeting criteria for a labeled indication (Early Intrauterine Pregnancy or Endogenous Cushing's Syndrome with Hyperglycemia).
Contraindicated	Confirmed or suspected ectopic pregnancy; Chronic adrenal failure; Hemorrhagic disorders or concurrent anticoagulant therapy; Known allergy to mifepristone; Inherited porphyrias.
Not Recommended	Severe hepatic impairment; Severe renal impairment; Breastfeeding women; Pediatric patients (safety not established).

Age-Related and Conditional Restrictions

Use in the pediatric population (under 18 years) is not established and generally not recommended. While the drug is approved for use in adults, caution is often advised for older adults due to the potential for decreased organ function.

For women of childbearing potential receiving the Cushing's syndrome indication, use is contraindicated during pregnancy, and regulatory agencies mandate the use of effective non-hormonal contraception during treatment and for a specified time after therapy concludes. Use in patients with an Intrauterine Device (IUD) is contraindicated unless the device is removed prior to administration.

Official Contraindicated Combinations

Certain co-administrations are formally prohibited based on regulatory labeling due to the risk of severe interaction. These combinations include concurrent long-term systemic glucocorticoid therapy, which Zacafemyl antagonizes due to its antiglucocorticoid activity. Co-administration with anticoagulant therapy or in the presence of hemorrhagic disorders is also strictly prohibited, as this significantly increases the risk of excessive bleeding.

Documented Exposure Modification

Zacafemyl is metabolized primarily via the CYP3A4 enzyme, leading to clinically relevant pharmacokinetic interactions:

Substance Category	Interaction Effect	Example Substances
Strong CYP3A4 Inhibitors	Expected to increase Zacafemyl plasma exposure.	Ketoconazole, Itraconazole, Erythromycin, Grapefruit Juice.
Strong CYP3A4 Inducers	Expected to reduce Zacafemyl plasma exposure.	Rifampin, Phenytoin, St. John’s Wort.

Conversely, Zacafemyl acts as an inhibitor of CYP3A4, which may result in an increase in the plasma concentrations of co-administered drugs that have a narrow therapeutic range (e.g., Cyclosporine, Fentanyl).

Procedural and Population Constraints

For regimens requiring Misoprostol, the regulatory label mandates a specific time separation: Misoprostol must be administered 24 to 48 hours following Zacafemyl administration. Furthermore, official documents note that use is not recommended in patients with severe hepatic disease due to clearance concerns, while no dose adjustment is formally recommended for renal impairment.

Zacafemyl, which is mifepristone, functions as a synthetic steroid with dual antagonist activity primarily targeting intracellular nuclear receptors. Its primary biological targets are the progesterone receptor (PR) and the glucocorticoid receptor (GR).

At the PR, the molecule acts as a competitive antagonist, binding to the receptor with high affinity, preventing the interaction of endogenous progesterone. This receptor blockade inhibits the normal PR-mediated gene transcription pathway, which regulates the cellular processes in the endometrium and myometrium. The interruption of this signaling cascade leads to a physiological cascade that includes the release of endogenous prostaglandins from the decidua and an increase in the sensitivity of the myometrium to the contractile effects of prostaglandins. This system-level modulation results in uterine contractility and endometrial disruption.

Separately, Zacafemyl also functions as a competitive antagonist at the GR, blocking the binding of cortisol. This interaction disrupts the intracellular signaling cascade regulated by the glucocorticoid pathway, particularly within tissues responsive to cortisol, modulating the overall hypothalamic-pituitary-adrenal (HPA) axis.

How Zacafemyl is Used: Official Dosing and Administration

Zacafemyl (Mifepristone) is an oral tablet with two distinct dosing protocols. The route of administration is strictly oral for the tablet, though one use involves a two-drug sequential regimen with a second medication administered buccally or vaginally.

Standard Labeled Dosing Regimens

Indication	Zacafemyl Dosing Protocol	Administration Detail
Early Pregnancy Management	A single dose of 200 mg orally.	Must be followed by a second medication 24 to 48 hours later, and requires a follow-up visit 7–14 days after the Zacafemyl dose.
Hyperglycemia in Cushing's Syndrome	Start at 300 mg orally, once daily.	Dose is gradually increased in 300 mg increments, but no more frequently than once every two to four weeks, up to a maximum of 1200 mg.

Contextual and Population-Specific Rules

For the Cushing's syndrome indication, Zacafemyl is taken with a meal to ensure proper intake. The tablets must be swallowed whole and should not be split, crushed, or chewed.

Special maximum dose limits exist for patients with underlying conditions. For instance, the maximum daily dose is limited to 600 mg for adult patients with established renal impairment or mild to moderate hepatic impairment. Safety and efficacy for the Cushing's syndrome use have not been established in patients under 18 years of age.

Research Evidence / Overview of Studies for Zacafemyl

---

Evidence for Medical Termination of Early Intrauterine Pregnancy

Zacafemyl was studied for this specific use through multiple large-scale randomized controlled trials (RCTs) and systematic reviews. Research examined short-term studies to observe the patterns related to Zacafemyl in combination with a second medication, misoprostol, which is a required part of the regimen. Researchers examined outcomes related to the complete expulsion of the pregnancy, monitoring the need for any follow-up surgical procedure. These studies primarily included pregnant adults who were up to 70 days into their gestation period.

Research highlights the measurements documented, such as the percentage of participants whose outcomes matched the criteria for a complete termination without requiring additional intervention. The evidence base here reflects the consistent use of large-scale, pivotal trials. Long-term outcomes related to women's reproductive health following the study period are not fully established in the initial trials.

---

Evidence for Managing High Blood Sugar in Endogenous Cushing's Syndrome

The research explored Zacafemyl's use in individuals with high blood sugar related to Cushing's syndrome, focusing on a specific patient group: adults who had failed surgery or were not surgical candidates. Research explored the outcomes related to systemic or functional imbalance, such as changes in markers of glucose control (e.g., HbA1c and plasma glucose) and patient-reported outcomes describing perceived discomfort. Findings were often based on intermediate-term observation, typically tracking participants over about six months.

The small sample sizes in the evidence base contribute to the evidence quality being categorized as moderate. Data are still emerging, and certainty remains low regarding the long-term durability of any measured changes beyond the initial observation period. Data for certain groups, such as the frail older adult population with comorbidities, remain insufficient.

---

Evidence for Managing Uterine Fibroids

Research explored its application in conditions characterized by functional limitations, specifically symptomatic uterine fibroids. Studies included randomized controlled trials and observational settings evaluating daily-life functioning related to bleeding and pain. Researchers examined outcomes describing episodic or acute changes, focusing on the reduction in heavy menstrual bleeding and the change in fibroid volume as confirmed by imaging.

Measurements of uterine or fibroid volume change, observed through imaging, were reported during the trials. Long-term effects are not fully established; there is limited information for how fibroid volume or symptoms are maintained after the medication is discontinued. Comparative evidence against surgery or other medical options for large-volume fibroids is often lacking.

Key Studies & References Mifepristone for Treatment of Metabolic Syndrome: Beyond Cushing's Syndrome - Frontiers in Pharmacology

Common questions about Zacafemyl (FAQ)

Q: How long do I need to use birth control after stopping the Cushing's syndrome treatment?

A: The official label specifies the use of effective non-hormonal contraception during treatment for the Cushing’s syndrome indication. Regulatory documents indicate that contraception is to be used for at least 1 month after the treatment with Zacafemyl has been stopped.

Q: Is there a different maximum dose for older patients taking it for Cushing’s?

A: The official maximum daily dose is set at 1200 mg. Regulatory information specifies dose limitations for patients with established renal impairment (kidney problems) or hepatic impairment (liver problems). The prescribing information does not list a different maximum dose based on older age alone.

Q: How is the 200 mg dose for early pregnancy taken?

A: The official dosing protocol involves a single 200 mg Zacafemyl tablet taken orally (by mouth). This dose is part of a two-step regimen and is followed by a second medication, misoprostol, 24 to 48 hours later. The second medication, misoprostol, is administered buccally (dissolved in the cheek pouch).

Q: Can I split or crush the tablet if I have trouble swallowing?

A: Official instructions indicate that the Zacafemyl tablets must be swallowed whole. They should not be split, crushed, or chewed, according to the official product label.

Q: What happens if I miss a dose of Zacafemyl for my Cushing's syndrome?

A: Official patient information describes the action to take if a dose is missed: it should be taken as soon as possible. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed. The guidance states that a double dose should not be taken to compensate for a missed dose.

Q: Does Zacafemyl treat other conditions besides the two main ones?

A: According to the official prescribing information, Zacafemyl is currently FDA-approved and formally indicated for two specific purposes: the medical termination of early pregnancy and the management of high blood sugar in endogenous Cushing's syndrome. The medication is only indicated for its two approved uses.

Q: Can Zacafemyl treat my Type 2 diabetes?

A: The medication is approved for controlling high blood sugar (hyperglycemia) only in adults who have endogenous Cushing's syndrome and who have also developed Type 2 Diabetes Mellitus or Glucose Intolerance. It is not indicated or approved for the treatment of general Type 2 diabetes.

Q: How long after taking the 200mg dose can I breastfeed my child again?

A: The active ingredient in this medication is documented to be excreted into human milk. Official information suggests that breastfeeding is generally not recommended during use. Some authoritative sources suggest that, to minimize potential exposure, pumping and discarding milk may be recommended for up to 18 to 21 days after the last dose.

How to Store and Dispose of Zacafemyl?

This medication must be stored according to specific regulatory requirements to maintain its stability. Store Zacafemyl tablets at room temperature, ensuring the storage location is away from excess heat and moisture. The medication must remain in its original container with the cap tightly closed.

Storage Requirement	Condition
Temperature	Room temperature
Protection	Avoid excess heat and moisture
Packaging	Keep in original, tightly closed container

For child safety, the medicine must be stored in a location that is out of the sight and reach of children. When disposing of unused or expired Zacafemyl, follow the official guidance. The preferred method is to use a secure drug take-back program. If no take-back program is available, the tablets should be mixed with an unappealing substance and sealed in a container before being placed in the household trash; do not flush the tablets down the toilet.